Research Analysts Issue Forecasts for COGT FY2026 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Leerink Partnrs lifted their FY2026 EPS estimates for Cogent Biosciences in a research report issued on Monday, April 28th. Leerink Partnrs analyst A. Berens now anticipates that the technology company will earn ($1.48) per share for the year, up from their previous forecast of ($1.49). The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The technology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03.

A number of other equities analysts have also recently weighed in on COGT. Needham & Company LLC reiterated a "hold" rating on shares of Cogent Biosciences in a report on Wednesday, February 26th. Scotiabank assumed coverage on Cogent Biosciences in a report on Friday, March 7th. They issued a "sector outperform" rating and a $17.00 target price for the company. HC Wainwright dropped their price objective on shares of Cogent Biosciences from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, January 14th. Piper Sandler raised Cogent Biosciences to a "strong-buy" rating in a research note on Friday, March 7th. Finally, Wedbush reissued a "neutral" rating and set a $11.00 price target on shares of Cogent Biosciences in a research note on Tuesday, February 25th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Cogent Biosciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $14.43.

Cogent Biosciences Stock Down 10.3 %

Shares of Cogent Biosciences stock traded down $0.58 during mid-day trading on Thursday, reaching $5.00. 690,163 shares of the stock traded hands, compared to its average volume of 1,257,949. The stock has a market capitalization of $568.71 million, a PE ratio of -2.01 and a beta of 1.91. Cogent Biosciences has a fifty-two week low of $3.72 and a fifty-two week high of $12.61. The business has a 50-day moving average of $5.84 and a 200 day moving average of $7.91.

Hedge Funds Weigh In On Cogent Biosciences

A number of hedge funds have recently modified their holdings of COGT. CWM LLC increased its stake in Cogent Biosciences by 11,869.9% in the 1st quarter. CWM LLC now owns 8,738 shares of the technology company's stock valued at $52,000 after buying an additional 8,665 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in shares of Cogent Biosciences in the fourth quarter valued at approximately $78,000. Hsbc Holdings PLC bought a new stake in shares of Cogent Biosciences during the 4th quarter worth $81,000. KLP Kapitalforvaltning AS acquired a new position in Cogent Biosciences in the 4th quarter valued at $88,000. Finally, E Fund Management Co. Ltd. acquired a new position in Cogent Biosciences during the 4th quarter worth $89,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.